Valvular & structural heart disease
Transcatheter valve-in-valve versus redo-surgical valve replacement for mitral bioprosthetic valve dysfunction: rationale and design of the SURVIV randomised trial
Study context
- Population
- Patients with mitral bioprosthetic valve dysfunction (BVD) suitable for surgical redo-mitral valve replacement (rMVR) or transcatheter mitral valve-in-valve (mViV)planned enrolment
- Participants
- 150 patients
- Planned comparison
- Transcatheter mViV vs surgical rMVR for mitral BVD
- Primary endpoint
- Composite of:
- All-cause mortality
- Disabling stroke
- Follow-up
- 12 months
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Transcatheter valve-in-valve versus redo-surgical valve replacement for mitral bioprosthetic valve dysfunction: rationale and design of the SURVIV randomised trial. EuroIntervention. Published 16 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →